{"id":"NCT01020448","sponsor":"Ipsen","briefTitle":"Effect of Triptorelin (Decapeptyl速) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer","officialTitle":"Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2011-11","completion":"2013-06","firstPosted":"2009-11-25","resultsPosted":"2015-07-15","lastUpdate":"2019-01-30"},"enrollment":339,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Triptorelin (Decapeptyl速)","otherNames":[]}],"arms":[{"label":"Triptorelin (Decapeptyl速) 22.5 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the effect of an initial hormonal treatment gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and TMPRSS2-ERG), in patients with histologically confirmed and advanced stages of prostate cancer. Their characteristics, according to risk factors such as PSA and Gleason score will be determined at baseline and 1, 3 and 6 month post-treatment.","primaryOutcome":{"measure":"PCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNA","timeFrame":"At month 6 post-treatment","effectByArm":[{"arm":"Triptorelin (Decapeptyl速) 22.5 mg","deltaMin":232,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":59,"countries":["Belgium","Denmark","France","Italy","Latvia","Lithuania","Netherlands","Romania","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":325},"commonTop":["Hot flush"]}}